SEC Form 4 · accession 0001140361-17-029596
Sienna Biopharmaceuticals, Inc. · SNNA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Erle T Mast
Director
Period of report
Aug 1, 2017
Accepted (ET)
Aug 1, 2017 · 4:24 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001656328
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 1, 2017 | P | 6,700 | $15.00 | A | 6,700 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The Reporting Person purchased the shares of the Issuer's common stock in connection with the Issuer's initial public offering at the offering price of $15.00 per share.